New biologic aims to tackle stubborn high triglycerides
NCT ID NCT07680829
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 3 trial tests an investigational injectable drug called DR10624 in adults with severe hypertriglyceridemia (very high blood fats) that remains high despite standard treatment. Participants continue their usual omega-3 therapy and receive weekly injections of DR10624 or a placebo. The study measures how much triglycerides drop over 26 weeks and checks safety and other lipid levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DR10624 (injectable biologic) plus icosapent ethyl (oral omega-3)
What this could lead to
If successful, this could offer a new add-on treatment option for people with severe high triglycerides that are not controlled by current therapy.
What could go wrong
This is a phase 3 trial, but the drug is still investigational. It may not prove effective or could have side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HYPERTRIGLYCERIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pegozafermin for Severe Hypertriglyceridemia (NCT05852431)
- ION775 for Hypertriglyceridemia Trial (NCT07604974)
- Olezarsen for High Triglycerides & Heart Disease NCT05355402
- DR10624 for Severe Hypertriglyceridemia Trial (NCT06555640)
- Olezarsen Extension Study for Severe Hypertrigly NCT05681351
- Solbinsiran for Severe High Triglycerides – NCT07269210
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, China